Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara ® (sarilumab) and Praluent ® (alirocumab) PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi ...

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Following the equity investment and strategic collaborations, a Sanofi representative will join Adagene ... the SAFEbody platform can be applied to a wide variety of antibody-based ...

Sanofi a nnounces €300 m illion collaboration with Blackstone Life Sciences to a dvance an i nnovative t reatment for m ultiple m yeloma. Investment will accelerate the overall Sarclisa ...

Terms of the CollaborationAs previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research ...

Within in the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think U.S. sales growth can rebound ...

PARIS, Nov 29 (Reuters) - French pharmaceutical company Sanofi-Aventis SA said on Thursday it was expanding its collaboration agreement with U.S. biotech partner Regeneron Pharmaceuticals Inc and ...

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody formatSelection of IPH6101/SAR443 ...

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.